4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-020087
PRESIDENT AND CEO sold 12,500 shares at an average $22.52 ($281,518)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kintz Samuel PRESIDENT AND CEO | 2025-07-17 | Sale 10b5-1 | −4,150 | $21.58 | $89,552 | 948,742 | I |
| Kintz Samuel PRESIDENT AND CEO | 2025-07-17 | Sale 10b5-1 | −4,687 | $22.69 | $106,360 | 944,055 | I |
| Kintz Samuel PRESIDENT AND CEO | 2025-07-17 | Sale 10b5-1 | −3,663 | $23.37 | $85,607 | 940,392 | I |
| Open-market sales · 12,500 sh · avg $22.52 · $281,518 | |||||||
Loading xslF345X05/form4-07212025_110705.xml…